To establish the Commission on Sustaining Medicare and Social Security, and for other purposes.
Summary
HR9089 is a procedural bill to establish a commission studying Medicare and Social Security sustainability. It has no direct funding, no mandates, and no near-term market impact. The bill is in early stage, referred to two committees, with no further action.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR9089 is a study commission bill with zero direct market impact.
- 2.No funding, mandates, or regulatory changes are included.
- 3.The bill is in early legislative stage; no near-term action expected.
Market Implications
No market implications. The bill is purely procedural and does not affect any company's revenue, costs, or competitive position. Investors should ignore this legislation until substantive provisions emerge.
Full Analysis
On June 2, 2026, Representative Bilirakis (R-FL) introduced HR9089, a bill to establish the Commission on Sustaining Medicare and Social Security. The bill was referred to the House Ways and Means and Energy and Commerce Committees. It remains in early legislative stage with no hearings, markups, or votes scheduled. The bill does not authorize or appropriate any funding; it only creates a study commission. No specific policy mechanisms, mandates, or incentives are included. The legislative path is long: committee consideration, potential markup, House floor vote, Senate passage, and presidential action. Given the procedural nature and early stage, market impact is negligible. No tickers are affected because the bill lacks any direct economic mechanism. The commission's future recommendations could influence healthcare and retirement policy, but that is years away and highly uncertain.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Consolidated Appropriations Act, 2026
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026
Protecting Health Care and Lowering Costs Act of 2025
DELL FEDERAL SYSTEMS L.P: $602M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.